Progress in the safety of chimeric antigen receptor T cells therapy / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 65-67, 2021.
Article
Dans Chinois
| WPRIM
| ID: wpr-882240
ABSTRACT
Chimeric antigen receptor T cells (CAR-T) therapy is progressing rapidly, and its safety has been widely concerned. At the 62nd American Society of Hematology Annual Meeting, a series of reports on the mechanism, predictive indicators and treatment strategies of major adverse reactions were carried out. These reports have certain guiding significance for comprehensively improving the safety of CAR-T therapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Leukemia & Lymphoma
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS